Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DALYA Trial: Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Plasmablastic Lymphoma
NCT04915248Phase 2Recruiting
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jul 2022
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in plasmablastic lymphoma (PBL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Overall Response Rate at 30 months. Started Jul 2022; status: recruiting.
02
Drugs
daratumumab
03
Conditions
plasmablastic lymphoma (PBL)
Beyond the preview
Go deeper on NCT04915248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915248.